KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:待检查 入排置信度 0.85

New conversations in an old argument: Lessons learnt from the PIONEER randomised feasibility study in resectable stage III-N2 NSCLC.

Janelle Yorke Rgn, Sally Taylor, Corinne Faivre-Finn, Melissa B Perry, David Baldwin, Fiona Blackhall, Charlotte Eastwood, John Edwards, Seamus Grundy, Emily Harris, Neal Navani, Michael Peake, Sarah Rhodes, Jonathan Robson, Selina Tsim, Paul Van Schil, Ashleigh Ward, Ian Woolhouse, Matthew Evison

Lung Cancer 216 109387

PMID41930542
PMCID-
DOI10.1016/j.lungcan.2026.109387
发表日期2026-04-03
入排依据:The record describes a randomized feasibility study for a future Phase III trial, but it is not itself a definitive Phase III trial. The primary outcomes are feasibility and quality of life, not a time-to-event efficacy endpoint. No specific drug-containing intervention is part of the randomized comparison.
入排复审未纳入:The record describes a randomized feasibility study for a future Phase III trial, but it is not itself a definitive Phase III trial. The primary outcomes are feasibility and quality of life, not a time-to-event efficacy endpoint. No specific drug-containing intervention is part of the randomized comparison.
摘要

摘要

BACKGROUND: Stage III-N2 non-small cell lung cancer (NSCLC) accounts for ∼ 6% of NSCLC cases in the UK. Despite decades of research, no clear survival advantage has been demonstrated between surgical and non-surgical treatment strategies in cases considered resectable. The impact of these regimens on health-related quality of life (HRQoL) remains poorly understood. The PIONEER trial aimed to assess the feasibility of a future phase III randomised controlled trial (RCT) comparing surgical versus non-surgical multimodality treatment with HRQoL as a potential primary outcome. METHODS: PIONEER was a UK-based, 8-centre feasibility RCT recruiting patients with resectable stage III-N2 NSCLC. Patients were randomised 1:1 to surgical multimodality treatment or non-surgical treatment. Feasibility outcomes included recruitment rate, treatment adherence, and completion of HRQoL questionnaires (EORTC QLQ-C30). RESULTS: Of 276 screened patients, 52 (19%) were eligible, and 28 (54%) of these consented and were randomised. Uptake of randomised treatment was high (93%), but only 50% and 57% completed HRQoL questionnaires at 3 and 6 months, respectively. Completion of planned multimodality treatment occurred in 50% (surgery arm) and 65% (non-surgical arm). Central review showed 12% of "unresectable" patients were potentially eligible and highlighted variability between multi-disciplinary teams. CONCLUSIONS: A future phase III trial is unlikely to be feasible. We suggest future work in this area considers leveraging high-quality, real-world data to offer valuable insights into treatment patterns and outcomes in unselected populations.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。